A New Reimbursement System for Innovative Pharmaceuticals Combining Value-Based and Free Market Pricing (original) (raw)

The paper critiques a previous work discussing the methodology of pharmaceutical reimbursement in Sweden, particularly regarding the cut-off levels for cost-effectiveness and reimbursement rates. It highlights discrepancies in reported data on rejected applications for drug reimbursement from the Dental and Pharmaceutical Benefits Agency (TLV) and emphasizes the need for a comprehensive assessment of prescribing practices and opportunity costs. Additionally, it raises considerations for implementing patient access schemes to enhance drug value and discusses the balance between patient safety and new drug accessibility within the reimbursement framework.